These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24803420)

  • 1. Comment on "Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion".
    Gore A; Attar M; Pujara C; Neervannan S
    Mol Pharm; 2014 Jul; 11(7):2490-2. PubMed ID: 24803420
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion.
    Rahman Z; Xu X; Katragadda U; Krishnaiah YS; Yu L; Khan MA
    Mol Pharm; 2014 Mar; 11(3):787-99. PubMed ID: 24423028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality by design: understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function.
    Zidan AS; Sammour OA; Hammad MA; Megrab NA; Habib MJ; Khan MA
    Int J Pharm; 2007 Mar; 332(1-2):55-63. PubMed ID: 17169518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric flow field flow fractionation for the characterization of globule size distribution in complex formulations: A cyclosporine ophthalmic emulsion case.
    Qu H; Wang J; Wu Y; Zheng J; Krishnaiah YSR; Absar M; Choi S; Ashraf M; Cruz CN; Xu X
    Int J Pharm; 2018 Mar; 538(1-2):215-222. PubMed ID: 29341918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts.
    Lallemand F; Schmitt M; Bourges JL; Gurny R; Benita S; Garrigue JS
    Eur J Pharm Biopharm; 2017 Aug; 117():14-28. PubMed ID: 28315447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation.
    Li Y; Guan Q; Xu J; Zhang H; Liu S; Ding Z; Wang Q; Wang Z; Liu M; Zhao Y
    Colloids Surf B Biointerfaces; 2023 May; 225():113267. PubMed ID: 36940502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical considerations for measuring the globule size distribution of cyclosporine ophthalmic emulsions.
    Petrochenko PE; Pavurala N; Wu Y; Yee Wong S; Parhiz H; Chen K; Patil SM; Qu H; Buoniconti P; Muhammad A; Choi S; Kozak D; Ashraf M; Cruz CN; Zheng J; Xu X
    Int J Pharm; 2018 Oct; 550(1-2):229-239. PubMed ID: 30125649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions.
    Chennell P; Delaborde L; Wasiak M; Jouannet M; Feschet-Chassot E; Chiambaretta F; Sautou V
    Eur J Pharm Sci; 2017 Mar; 100():230-237. PubMed ID: 28131754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved extemporaneous formulation of cyclosporine ophthalmic drops.
    Mueller DW
    Am J Hosp Pharm; 1994 Dec; 51(24):3080-1. PubMed ID: 7856631
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in children.
    Hoehn ME; Kelly SR; Wilson MW; Walton RC
    Pediatr Blood Cancer; 2013 Jul; 60(7):E35-7. PubMed ID: 23335290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin - allergan. Ciclosporin - allergan, cyclosporin ophthalmic emulsion, cyclosporine - Allergan, Restasis.
    Drugs R D; 2003; 4(2):126-7. PubMed ID: 12718570
    [No Abstract]   [Full Text] [Related]  

  • 12. Self-assembling colloidal system for the ocular administration of cyclosporine A.
    Luschmann C; Tessmar J; Schoeberl S; Strauß O; Luschmann K; Goepferich A
    Cornea; 2014 Jan; 33(1):77-81. PubMed ID: 24162754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of lipid emulsion for ocular delivery of lipophilic drugs.
    Tamilvanan S; Benita S
    Eur J Pharm Biopharm; 2004 Sep; 58(2):357-68. PubMed ID: 15296961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailoring the PLATMC chain microstructure for stable cyclosporine A release.
    Kasperczyk J; Jelonek K; Gębarowska K; Dobrzyński P; Smola A
    J Control Release; 2011 Nov; 152 Suppl 1():e42-4. PubMed ID: 22195915
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoral: the new cyclosporine.
    Corbett J; Ross K
    ANNA J; 1998 Feb; 25(1):71-2. PubMed ID: 9543913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemistry matters!
    Novack GD
    Ocul Surf; 2017 Apr; 15(2):264-267. PubMed ID: 28137652
    [No Abstract]   [Full Text] [Related]  

  • 19. Unusual corneal deposit after the topical use of cyclosporine as eyedrops.
    Kachi S; Hirano K; Takesue Y; Miura M
    Am J Ophthalmol; 2000 Nov; 130(5):667-9. PubMed ID: 11078849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation.
    Yang SG
    Arch Pharm Res; 2010 Nov; 33(11):1835-42. PubMed ID: 21116787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.